Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

william a cook australia pty ltd -

Austrália - angličtina - APVMA (Australian Pesticides and Veterinary Medicines Authority)

epiglass (australia) pty ltd - cuprous oxide | diuron - antifouling - boat - exterior (antifouling) - fouling - for antifouling on boats

Egypt - angličtina - EDA (Egyptian Drug Authority)

تيسيرميد -

Singapur - angličtina - HSA (Health Sciences Authority)

cook south east asia pte ltd - general & plastic surgery - for use in the percutaneous dilation of tissue surrounding cardiac leads, indwelling catheters and foreign objects.

Malta - angličtina - Medicines Authority

anfarm hellas s.a. 4 achaias str. & trizinias 14564 kifissia, attiki, greece - ciprofloxacin - solution for infusion - ciprofloxacin 200 mg - antibacterials for systemic use

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

seacross pharmaceuticals limited - docetaxel anhydrous - concentrate for solution for infusion - 20 milligram(s)/millilitre - taxanes; docetaxel

Spojené štáty - angličtina - NLM (National Library of Medicine)

endo pharmaceuticals inc. - histrelin acetate (unii: qmg7hld1ze) (histrelin - unii:h50h3s3w74) - histrelin acetate 50 mg - vantas is indicated for the palliative treatment of advanced prostate cancer. vantas is contraindicated in patients who are hypersensitive to gonadotropin releasing hormone (gnrh) or gnrh agonist analogs. risk summary the safety and efficacy of vantas have not been established in females. based on findings in animal studies and its mechanism of action, vantas can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . expected hormonal changes that occur with vantas treatment increase the risk for pregnancy loss. the limited data with histrelin use in pregnant women are insufficient to determine a drug-associated risk for major birth defects or adverse developmental outcomes. in animal reproduction studies, administration of histrelin to pregnant rats and rabbits during the period of organogenesis caused an increase in fetal loss at clinically relevant exposures (see data) . advise pregnant patients and females of reproductive potential of the potential risk to the fetus. d

Izrael - angličtina - Ministry of Health

a.l. medi-market ltd. - docetaxel anhydrous - concentrate for solution for infusion - docetaxel anhydrous 20 mg / 1 ml - docetaxel - breast cancer : docetaxel seacross 20 mg/ml in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer .docetaxel seacross 20 mg/ml in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition .docetaxel seacross 20 mg/ml monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent .docetaxel seacross 20 mg/ml in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress her2 and who previously have not received chemotherapy for metastatic disease .docetaxel seacross 20 mg/ml in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline. doxorubicin and cyclophosphamide followed by docetaxel seacross 20 mg/ml in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with her2 over-expressing, node-positive or high risk node-negative, breast cancer .docetaxel seacross 20 mg/ml in combination with trastuzumab, and carboplatin (tch) is indicated for the adjuvant treatment of patients with her2 over-expressing, node-positive or high risk node-negative, breast cancer.non-small cell lung cancer : docetaxel seacross 20 mg/ml is indicated for the treatment of patients with advanced non-small cell lung carcinoma. ovarian cancer : docetaxel seacross 20 mg/ml is indicated for treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy .prostate cancer : docetaxel seacross 20 mg/ml in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer . esophageal cancer : docetaxel seacross 20 mg/ml for the treatment of esophageal cancer.gastric cancer : docetaxel seacross 20 mg/ml for the treatment of advanced gastric cancer.head and neck (scchn): docetaxel seacross 20 mg/ml as monotherapy in the treatment of patients with recurrent and/or metastasis squamos cell carcinoma of the head and neck after failure of a previous chemotherapy regimen.docetaxel seacross 20 mg/ml in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.